Plausibility of early and short acquisition windows for <sup>18</sup> F‐NAV4694 and <sup>18</sup> F‐florbetapir PET to expand clinical throughput

Acquiring NAV at 30-40 minutes or FBP at 40-50 minutes, with linear correction, is unlikely to change clinical management. Thus, 50% scan time reduction and 40% (NAV) or 20% (FBP) uptake time reduction is achievable. Importantly, the tracers have not reached steady-state at early windows, so accurate timing of the acquisition window is essential.

Authors

Vincent Doré (ORCID: https://orcid.org/0000-0002-8051-0558)
Graeme O’Keefe
Ashley Gillman (ORCID: https://orcid.org/0000-0001-9130-1092)
Pamela LaMontagne (ORCID: https://orcid.org/0000-0002-6752-8518)
C. Rowe
Jurgen Fripp
Pierrick Bourgeat
John C. Morris
Kun Huang
Tammie L.S. Benzinger
Victor L. Villemagne

Institutions

The University of Melbourne (AU)
University of Pittsburgh (US)
Washington University in St. Louis (US)
Florey Institute of Neuroscience and Mental Health (AU)
Australian e-Health Research Centre (AU)
Austin Health (AU)

Publication Details

Journal: Alzheimer s & Dementia
Published: 2025-12-01
DOI: https://doi.org/10.1002/alz70856_104290
Primary Topic: Amyloidosis: Diagnosis, Treatment, Outcomes
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Plausibility of early and short acquisition windows for ¹⁸ F‐NAV4694 and ¹⁸ F‐florbetapir PET to expand clinical throughput

Vincent Doré, Graeme O’Keefe, Ashley Gillman, Pamela LaMontagne et al.

Dec 1, 2025

Alzheimer s & Dementia

Amyloidosis: Diagnosis, Treatment, Outcomes

article

Plausibility of early and short acquisition windows for ¹⁸ F‐NAV4694 and ¹⁸ F‐florbetapir PET to expand clinical throughput

Vincent Doré, Graeme O’Keefe, Ashley Gillman, Pamela LaMontagne, C. Rowe, Jurgen Fripp, Pierrick Bourgeat, John C. Morris, Kun Huang, Tammie L.S. Benzinger, Victor L. Villemagne

December 1, 2025article en

Abstract

Acquiring NAV at 30-40 minutes or FBP at 40-50 minutes, with linear correction, is unlikely to change clinical management. Thus, 50% scan time reduction and 40% (NAV) or 20% (FBP) uptake time reduction is achievable. Importantly, the tracers have not reached steady-state at early windows, so accurate timing of the acquisition window is essential.

Alzheimer s & DementiaVol. 21(S2)

The University of Melbourne (AU), University of Pittsburgh (US), Washington University in St. Louis (US), Florey Institute of Neuroscience and Mental Health (AU), Australian e-Health Research Centre (AU), Austin Health (AU)

Decent work and economic growth

Openalex Percentile: Top 36%

Amyloidosis: Diagnosis, Treatment, Outcomes

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Plausibility of early and short acquisition windows for <sup>18</sup> F‐NAV4694 and <sup>18</sup> F‐florbetapir PET to expand clinical throughput — Vincent Doré, Graeme O’Keefe, et al. · Alzheimer s & Dementia (2025) | TGRS Research Map | TGRS